Background/Aims: There are several reports regarding intraductal papillary mucinous neoplasms (IPMNs) detected after the occurrence of acute pancreatitis. Although the presence of symptoms is regarded as a factor for predicting malignant IPMNs, there have been few reports demonstrating whether a history of acute pancreatitis is a predictor of malignancy. The aim of this study was to evaluate the relationship between a history of acute pancreatitis and clinicopathological features of IPMNs including the papillary subtype. Methods: The data of 150 IPMNs resected between 1990 and 2009 were retrospectively reviewed. They were classified into IPMNs with or without history of acute pancreatitis, and then the clinicopathological features were compared between the 2 groups. Results: Nineteen (13%) of the 150 patients had a history of acute pancreatitis. Nine of them had repeated episodes of pancreatitis; however, severe pancreatitis was uncommon. The diameter of the main pancreatic duct of the pancreatitis group was significantly larger than that of the nonpancreatitis group (p = 0.04). The pancreatitis group had a significantly higher frequency of carcinoma derived from IPMNs than the nonpancreatitis group (p = 0.03). The incidence of intestinal-type IPMNs in the pancreatitis group was significantly higher than that in the nonpancreatitis group (p < 0.001). Conclusion: Acute pancreatitis associated with IPMNs could predict malignant intestinal-type tumor.

Keywords:
Intraductal papillary mucinous neoplasm, Acute pancreatitis
1.
Salvia R, Fernandez-del Castillo C, Bassi C, et al: Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg 2004;239:678–685; discussion 685–677.
2.
Ringold DA, Shroff P, Sikka SK, et al: Pancreatitis is frequent among patients with side-branch intraductal papillary mucinous neoplasia diagnosed by eus. Gastrointest Endosc 2009;70:488–494.
3.
Pelletier AL, Hammel P, Rebours V, et al: Acute pancreatitis in patients operated on for intraductal papillary mucinous neoplasms of the pancreas: frequency, severity, and clinicopathologic correlations. Pancreas 2010; 39:658–661.
4.
Tanaka M, Kobayashi K, Mizumoto K, et al: Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol 2005;40:669–675.
5.
Furukawa T, Kloppel G, Volkan Adsay N, et al: Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005;447:794–799.
6.
Andrejevic-Blant S, Kosmahl M, Sipos B, et al: Pancreatic intraductal papillary-mucinous neoplasms: a new and evolving entity. Virchows Arch 2007;451:863–869.
7.
Tanaka M, Chari S, Adsay V, et al: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17–32.
8.
Terris B, Ponsot P, Paye F, et al: Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372–1377.
9.
Sohn TA, Yeo CJ, Cameron JL, et al: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788–797; discussion 797–789.
10.
Koizumi M, Takada T, Kawarada Y, et al: JPN guidelines for the management of acute pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg 2006;13:25–32.
11.
Kitagawa M, Naruse T, Hayakawa T, et al: Prediction of exacerbation of acute pancreatitis (in Japanese with English abstract). Suizou (J Jpn Panc Soc) 2001;16:95–102.
12.
Ogawa M, Hirota M, Hayakawa T, et al: Development and use of a new staging system for severe acute pancreatitis based on a nationwide survey in Japan. Pancreas 2002;25:325–330.
13.
Hirota M, Takada T, Kawarada Y, et al: JPN guidelines for the management of acute pancreatitis: severity assessment of acute pancreatitis. J Hepatobiliary Pancreat Surg 2006;13:33–41.
14.
Longnecker DS, Alder G, Hruban RH, et al: Intraductal papillary-mucinous neoplasms of the pancreas; in Hamilton SA, Aaltonen LA (eds): World Health Organization Classificaion of Tumuors; Pathology and Genetics of Tumours of the Digestive System. Lyon, IARC Press, 2000, pp 237–241.
15.
Suzuki Y, Atomi Y, Sugiyama M, et al: Cystic neoplasm of the pancreas: a Japanese multiinstitutional study of intraductal papillary mucinous tumor and mucinous cystic tumor. Pancreas 2004;28:241–246.
16.
Tibayan F, Vierra M, Mindelzun B, et al: Clinical presentation of mucin-secreting tumors of the pancreas. Am J Surg 2000;179:349–351.
17.
Retter J, Dinter D, Bersch C, et al: Acute recurrent pancreatitis curtaining an intraductal papillary mucinous tumor of the pancreas. J Gastrointestin Liver Dis 2007;16:445–447.
18.
Kitagawa Y, Unger TA, Taylor S, et al: Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg 2003;7:12–18; discussion 18–19.
19.
Sugiyama M, Izumisato Y, Abe N, et al: Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003;90:1244–1249.
20.
Adsay NV, Merati K, Basturk O, et al: Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an ‘intestinal’ pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004;28:839–848.
21.
Sadakari Y, Ohuchida K, Nakata K, et al: Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery 2010;147:812–817.
© 2011 S. Karger AG, Basel and IAP
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.